Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The role of drug susceptibility testing in M/XDR-TB. Too little and too late - Are we doing the right things?

Hoffner SE.

Int J Mycobacteriol. 2013 Dec;2(4):191-3. doi: 10.1016/j.ijmyco.2013.10.003. Epub 2013 Nov 1. No abstract available.

2.

The need for improved tuberculosis control.

Hoffner SE, Jonsson J.

Lancet Infect Dis. 2013 Sep;13(9):731-2. doi: 10.1016/S1473-3099(13)70150-6. Epub 2013 Jun 5. No abstract available.

PMID:
23759448
3.

Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras.

Alvarez-Corrales N, Ahmed RK, Rodriguez CA, Balaji KN, Rivera R, Sompallae R, Vudattu NK, Hoffner SE, Zumla A, Pineda-Garcia L, Maeurer M.

BMC Infect Dis. 2013 Mar 6;13:125. doi: 10.1186/1471-2334-13-125.

4.

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T.

Bull World Health Organ. 2012 Sep 1;90(9):693-8. doi: 10.2471/BLT.11.096644. Epub 2012 May 29.

5.

Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia L, Merza MA, Muntean I, Bwanga F, Joloba M, Hoffner SE.

Int J Mycobacteriol. 2012 Sep;1(3):124-30. doi: 10.1016/j.ijmyco.2012.08.001. Epub 2012 Aug 31.

6.

Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.

Engström A, Morcillo N, Imperiale B, Hoffner SE, Juréen P.

J Clin Microbiol. 2012 Jun;50(6):2026-33. doi: 10.1128/JCM.06664-11. Epub 2012 Mar 29.

7.

Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus.

Ahmed RK, Rohava Z, Balaji KN, Hoffner SE, Gaines H, Magalhaes I, Zumla A, Skrahina A, Maeurer MJ.

BMC Infect Dis. 2012 Feb 15;12:41. doi: 10.1186/1471-2334-12-41.

8.

Microevolution of extensively drug-resistant tuberculosis in Russia.

Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F.

Genome Res. 2012 Apr;22(4):735-45. doi: 10.1101/gr.128678.111. Epub 2012 Jan 31.

9.

Field assessment of the direct nitrate reductase assay for rapid detection of multidrug-resistant tuberculosis in Honduras.

Rosales S, Almendarez N, Membreño H, Hoffner SE, Pineda-Garcia L.

Int J Tuberc Lung Dis. 2011 Sep;15(9):1206-10, i. doi: 10.5588/ijtld.10.0697.

PMID:
21943847
10.

Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.

Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P.

J Antimicrob Chemother. 2011 Jun;66(6):1247-54. doi: 10.1093/jac/dkr109. Epub 2011 Mar 21.

PMID:
21427106
11.

Molecular diversity of Mycobacterium tuberculosis isolates from patients with tuberculosis in Honduras.

Rosales S, Pineda-García L, Ghebremichael S, Rastogi N, Hoffner SE.

BMC Microbiol. 2010 Aug 3;10:208. doi: 10.1186/1471-2180-10-208.

12.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23.

PMID:
20332195
13.

Ad fontes!

Hoffner SE, Salfinger M.

Int J Tuberc Lung Dis. 2010 Mar;14(3):260. No abstract available.

PMID:
20132612
14.

Evaluation of the nitrate reductase assay for rapid detection of extensively drug-resistant tuberculosis.

Rosales S, Pineda-García L, Andino N, Almendarez N, Membreño H, Hoffner SE.

Int J Tuberc Lung Dis. 2009 Dec;13(12):1542-9.

PMID:
19919774
15.

Results of the external quality assessment of Mycobacterium tuberculosis drug susceptibility testing in Russia, 2005-2007.

Shulgina MV, Malakhov VN, Hoffner SE, Haile M, Wright A.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1294-300.

PMID:
19793436
16.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.

PMID:
19633001
17.

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH, Hoffner SE.

Chest. 2009 Aug;136(2):420-425. doi: 10.1378/chest.08-2427. Epub 2009 Apr 6.

PMID:
19349380
18.

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Huitric E, Verhasselt P, Andries K, Hoffner SE.

Antimicrob Agents Chemother. 2007 Nov;51(11):4202-4. Epub 2007 Aug 20.

19.
20.

Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology.

Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE.

J Clin Microbiol. 2006 Jun;44(6):1925-9.

21.
22.

Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.

Juréen P, Werngren J, Hoffner SE.

Tuberculosis (Edinb). 2004;84(5):311-6.

PMID:
15207806
23.

Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis.

Mariam DH, Mengistu Y, Hoffner SE, Andersson DI.

Antimicrob Agents Chemother. 2004 Apr;48(4):1289-94.

24.

Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis.

Angeby KA, Werngren J, Toro JC, Hedström G, Petrini B, Hoffner SE.

Clin Microbiol Infect. 2003 Nov;9(11):1148-52.

26.

European recommendations on surveillance of antituberculosis drug resistance.

Schwoebel V, Lambregts CS, Moro ML, Drobniewski F, Hoffner SE, Raviglione MC, Rieder HL.

Euro Surveill. 2000 Oct;5(10):104-106.

PMID:
12631965
27.

In vitro activity of thiacetazone on mycobacterial species belonging to the Mycobacterium tuberculosis complex.

Abate G, Koivula T, Hoffner SE.

Int J Tuberc Lung Dis. 2002 Oct;6(10):933-5.

PMID:
12365582
28.

Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.

Krüüner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE, Mikelsaar M.

Clin Infect Dis. 2002 Jul 15;35(2):146-55. Epub 2002 Jun 14.

PMID:
12087520
30.
31.

Spread of drug-resistant pulmonary tuberculosis in Estonia.

Krüüner A, Hoffner SE, Sillastu H, Danilovits M, Levina K, Svenson SB, Ghebremichael S, Koivula T, Källenius G.

J Clin Microbiol. 2001 Sep;39(9):3339-45.

32.

Antimicrobial susceptibility of Mycobacterium marinum determined by E-test and agar dilution.

Werngren J, Olsson-Liljequist B, Gezelius L, Hoffner SE.

Scand J Infect Dis. 2001;33(8):585-8.

PMID:
11525351
33.

Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG.

Abate G, Hoffner SE, Thomsen VO, Miörner H.

Eur J Clin Microbiol Infect Dis. 2001 May;20(5):329-33.

PMID:
11453593
34.

In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis.

Linde CM, Hoffner SE, Refai E, Andersson M.

J Antimicrob Chemother. 2001 May;47(5):575-80.

PMID:
11328767
35.

Tuberculosis as an occupational hazard for health care workers in Estonia.

Krüüner A, Danilovitsh M, Pehme L, Laisaar T, Hoffner SE, Katila ML.

Int J Tuberc Lung Dis. 2001 Feb;5(2):170-6.

PMID:
11258511
36.

Comparison of Mycobacterium avium complex (MAC) strains from pigs and humans in Sweden by random amplified polymorphic DNA (RAPD) using standardized reagents.

Ramasoota P, Chansiripornchai N, Källenius G, Hoffner SE, Svenson SB.

Vet Microbiol. 2001 Feb 12;78(3):251-9.

PMID:
11165069
37.

Mycobacterium interjectum: a new pathogen in humans?

Rustscheff S, Maroti L, Holberg-Petersen M, Steinbakk M, Hoffner SE.

Scand J Infect Dis. 2000;32(5):569-71.

PMID:
11055671
38.

Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group.

Schwoebel V, Lambregts-van Weezenbeek CS, Moro ML, Drobniewski F, Hoffner SE, Raviglione MC, Rieder HL.

Eur Respir J. 2000 Aug;16(2):364-71. Review.

39.

Improved sputum microscopy for a more sensitive diagnosis of pulmonary tuberculosis.

Angeby KA, Alvarado-Gálvez C, Pineda-García L, Hoffner SE.

Int J Tuberc Lung Dis. 2000 Jul;4(7):684-7.

PMID:
10907772
40.

Evolution and clonal traits of Mycobacterium tuberculosis complex in Guinea-Bissau.

Källenius G, Koivula T, Ghebremichael S, Hoffner SE, Norberg R, Svensson E, Dias F, Marklund BI, Svenson SB.

J Clin Microbiol. 1999 Dec;37(12):3872-8.

41.

Tuberculosis in HIV-infected patients in Honduras.

Andersson K, Aronsson M, Alvarado-Galvez C, Pineda-Garcia L, Hoffner SE.

Int J Tuberc Lung Dis. 1999 Jul;3(7):640. No abstract available.

PMID:
10423230
43.

Drug resistant tuberculosis in Estonia.

Kruuner A, Sillastu H, Danilovitsh M, Levina K, Svenson SB, Källenius G, Hoffner SE.

Int J Tuberc Lung Dis. 1998 Feb;2(2):130-3.

PMID:
9562123
44.

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

Hoffner SE, Gezelius L, Olsson-Liljequist B.

J Antimicrob Chemother. 1997 Dec;40(6):885-8.

PMID:
9462443
45.
46.

Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.

Abate G, Hoffner SE.

Diagn Microbiol Infect Dis. 1997 Jul;28(3):119-22.

PMID:
9294701
47.

Mycobacterium fortuitum complex in Sweden during an 11-year period.

Svahn A, Hoffner SE, Petrini B, Källenius G.

Scand J Infect Dis. 1997;29(6):573-7.

PMID:
9571737
48.
49.

Direct detection of Mycobacterium tuberculosis in sputum samples from Guinea Bissau by an rRNA target-amplified test system.

Hoffner SE, Norberg R, Carlos Toro J, Winqvist N, Koivula T, Dias F, Svenson SB, Källenius G.

Tuber Lung Dis. 1996 Feb;77(1):67-70.

PMID:
8733417
50.

RNA amplification for direct detection of mycobacterium tuberculosis in respiratory samples.

Hoffner SE, Cristea M, Klintz L, Petrini B, Kallenius G.

Scand J Infect Dis. 1996;28(1):59-61.

PMID:
9122635

Supplemental Content

Loading ...
Support Center